Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Enhertu Delivers Stellar PIII Data in HER2 Low Breast Cancer
Daiichi Sankyo said on June 5 that its antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) reduced the risk of disease progression or death by 50% versus chemotherapy in a global PIII trial enrolling patients with HER2 low breast cancer. The DESTINY-Breast04…
To read the full story
Related Article
- Enhertu Wins EU Approval for HER2 Low Breast Cancer
January 27, 2023
- Enhertu Nabs EU Nod for Second-Line Gastric Cancer, CHMP OK for HER2 Low Breast Cancer
December 20, 2022
- Enhertu Grabs US Approval for HER2 Low Breast Cancer: Daiichi Sankyo/AZ
August 9, 2022
- Enhertu Gets FDA’s Priority Review for HER2 Low Breast Cancer
July 26, 2022
- Enhertu Filed for HER2 Low Breast Cancer in Japan: Daiichi Sankyo
June 28, 2022
- EMA Starts Enhertu Review for HER2 Low Breast Cancer
June 23, 2022
- Enhertu Hits PFS, OS Goals in HER2 Low Breast Cancer
February 22, 2022
BUSINESS
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
- AstraZeneca Sees Broad Pipeline, AI Powering 50-Plus Approval Goal
August 5, 2026
- Voyxact PIII Data Confirm Kidney Function Stabilization in IgAN
August 5, 2026
- Perioperative Imfinzi Seen Advancing Gastric Cancer Care: Oncologist
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…